SCHEMBL24673136

SCHEMBL24673136

Nc1ncnc2c1ncn2[C@@H]1O[C@@]2(C[C@H]2O)C(O)C1O

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRMT5 O14744 1/20 0.80
▸ WDR77 Q9BQA1 1/20 0.80
▸ AHCY P23526 10/20 0.56
▸ ADORA2A P29274 2/20 0.56
▸ ADORA2B P29275 2/20 0.56
▸ DPP4 P27487 1/20 0.56
▸ MEN1 O00255 1/20 0.56
▸ SLC28A1 O00337 1/20 0.56
▸ MAP3K7 O43318 1/20 0.56
▸ SLC28A2 O43868 1/20 0.56
▸ GAPDH P04406 1/20 0.56
▸ ADORA3 P0DMS8 1/20 0.56
▸ MAPK1 P28482 1/20 0.56
▸ ADORA1 P30542 1/20 0.56
▸ STAT6 P42226 1/20 0.56
▸ PI4KA P42356 1/20 0.56
▸ KMT2A Q03164 1/20 0.56
▸ SMN1; SMN2 Q16637 1/20 0.56
▸ PI4K2B Q8TCG2 1/20 0.56
▸ DOT1L Q8TEK3 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24673475 1.00 PRMT5 (0.80) PRMT5WDR77AHCYADORA2AADORA2B
SCHEMBL24673580 1.00 PRMT5 (0.80) PRMT5WDR77AHCYADORA2AADORA2B
SCHEMBL24673581 1.00 PRMT5 (0.80) PRMT5WDR77AHCYADORA2AADORA2B
SCHEMBL24673573 0.89 PRMT5 (1.00) PRMT5WDR77AHCYADORA2AADORA2B
SCHEMBL22797623 0.89 PRMT5 (1.00) PRMT5WDR77AHCYADORA2AADORA2B
SCHEMBL22799077 0.89 PRMT5 (1.00) PRMT5WDR77AHCYADORA2AADORA2B
SCHEMBL24673967 0.89 PRMT5 (1.00) PRMT5WDR77AHCYADORA2AADORA2B
SCHEMBL24673534 0.89 PRMT5 (1.00) PRMT5WDR77AHCYADORA2AADORA2B
SCHEMBL22797656 0.89 PRMT5 (1.00) PRMT5WDR77AHCYADORA2AADORA2B
SCHEMBL22797659 0.89 PRMT5 (1.00) PRMT5WDR77AHCYADORA2AADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220275018-A1 NOVEL SPIROBICYCLIC INTERMEDIATES JANSSEN PHARMACEUTICA NV (BE) 2022-09-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220275018-A1 NOVEL SPIROBICYCLIC INTERMEDIATES NME2, SLC28A1, SLC28A2 PRMT5 3663/4885WDR77 3289/4885AHCY 998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback